These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25011112)

  • 21. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for colorectal cancer.
    Koido S; Ohkusa T; Homma S; Namiki Y; Takakura K; Saito K; Ito Z; Kobayashi H; Kajihara M; Uchiyama K; Arihiro S; Arakawa H; Okamoto M; Gong J; Tajiri H
    World J Gastroenterol; 2013 Dec; 19(46):8531-42. PubMed ID: 24379570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immune contexture in cancer prognosis and treatment.
    Fridman WH; Zitvogel L; Sautès-Fridman C; Kroemer G
    Nat Rev Clin Oncol; 2017 Dec; 14(12):717-734. PubMed ID: 28741618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell modulation by cyclophosphamide for tumour therapy.
    Hughes E; Scurr M; Campbell E; Jones E; Godkin A; Gallimore A
    Immunology; 2018 May; 154(1):62-68. PubMed ID: 29460448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAMA Oncology Patient Page. Immune Checkpoint Inhibitors.
    West HJ
    JAMA Oncol; 2015 Apr; 1(1):115. PubMed ID: 26182315
    [No Abstract]   [Full Text] [Related]  

  • 29. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
    Atreya I; Neurath MF
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.
    Allison KE; Coomber BL; Bridle BW
    Immunology; 2017 Oct; 152(2):175-184. PubMed ID: 28621843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The inflammatory microenvironment in brain metastases: potential treatment target?
    Berghoff AS; Preusser M
    Chin Clin Oncol; 2015 Jun; 4(2):21. PubMed ID: 26112807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
    Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
    Front Immunol; 2020; 11():573326. PubMed ID: 33178201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yin-yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy.
    Zhang Z; Zhu Y; Wang Z; Zhang T; Wu P; Huang J
    Cancer Lett; 2017 May; 393():1-7. PubMed ID: 28216374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
    Duechler M; Peczek L; Zuk K; Zalesna I; Jeziorski A; Czyz M
    Immunobiology; 2014 Feb; 219(2):158-65. PubMed ID: 24091277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer.
    Palazón A; Aragonés J; Morales-Kastresana A; de Landázuri MO; Melero I
    Clin Cancer Res; 2012 Mar; 18(5):1207-13. PubMed ID: 22205687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings.
    Goruganthu MUL; Shanker A; Dikov MM; Carbone DP
    Front Immunol; 2020; 11():1958. PubMed ID: 32922403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.
    Vasaturo A; Verdoes M; de Vries J; Torensma R; Figdor CG
    Immunobiology; 2015 Feb; 220(2):243-8. PubMed ID: 25466585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Directing Traffic: How to Effectively Drive T Cells into Tumors.
    Anandappa AJ; Wu CJ; Ott PA
    Cancer Discov; 2020 Feb; 10(2):185-197. PubMed ID: 31974169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
    Sharabi AB; Lim M; DeWeese TL; Drake CG
    Lancet Oncol; 2015 Oct; 16(13):e498-509. PubMed ID: 26433823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.